Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Bronchoalveolar cell differential count and the number of asbestos bodies correlate with survival in patients with asbestosis.

Keskitalo E, Varis L, Bloigu R, Kaarteenaho R.

Occup Environ Med. 2019 Oct;76(10):765-771. doi: 10.1136/oemed-2018-105606. Epub 2019 Jul 22. Review.

PMID:
31331950
2.

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.

Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Kankaanranta H, Koli K, Vahlberg T, Myllärniemi M.

ERJ Open Res. 2019 Jul 8;5(3). pii: 00170-2018. doi: 10.1183/23120541.00170-2018. eCollection 2019 Jul.

3.

Inorganic particulate matter in the lung tissue of idiopathic pulmonary fibrosis patients reflects population density and fine particle levels.

Mäkelä K, Ollila H, Sutinen E, Vuorinen V, Peltola E, Kaarteenaho R, Myllärniemi M.

Ann Diagn Pathol. 2019 Jun;40:136-142. doi: 10.1016/j.anndiagpath.2019.04.011. Epub 2019 Apr 24.

4.

Cadherin-11-mediated adhesion of macrophages to myofibroblasts establishes a profibrotic niche of active TGF-β.

Lodyga M, Cambridge E, Karvonen HM, Pakshir P, Wu B, Boo S, Kiebalo M, Kaarteenaho R, Glogauer M, Kapoor M, Ask K, Hinz B.

Sci Signal. 2019 Jan 15;12(564). pii: eaao3469. doi: 10.1126/scisignal.aao3469.

PMID:
30647145
5.

Haploinsufficiency of A20 impairs protein-protein interactome and leads into caspase-8-dependent enhancement of NLRP3 inflammasome activation.

Rajamäki K, Keskitalo S, Seppänen M, Kuismin O, Vähäsalo P, Trotta L, Väänänen A, Glumoff V, Keskitalo P, Kaarteenaho R, Jartti A, Hautala N, Jackson P, Nordström DC, Saarela J, Hautala T, Eklund KK, Varjosalo M.

RMD Open. 2018 Oct 17;4(2):e000740. doi: 10.1136/rmdopen-2018-000740. eCollection 2018.

6.

Biallelic mutations in human NHLRC2 enhance myofibroblast differentiation in FINCA disease.

Paakkola T, Salokas K, Miinalainen I, Lehtonen S, Manninen A, Kaakinen M, Ruddock LW, Varjosalo M, Kaarteenaho R, Uusimaa J, Hinttala R.

Hum Mol Genet. 2018 Dec 15;27(24):4288-4302. doi: 10.1093/hmg/ddy298.

PMID:
30239752
7.

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.

Pesonen I, Carlson L, Murgia N, Kaarteenaho R, Sköld CM, Myllärniemi M, Ferrara G.

Multidiscip Respir Med. 2018 May 14;13:14. doi: 10.1186/s40248-018-0126-7. eCollection 2018.

8.

The neutrophil-mobilizing cytokine interleukin-26 in the airways of long-term tobacco smokers.

Che KF, Tufvesson E, Tengvall S, Lappi-Blanco E, Kaarteenaho R, Levänen B, Ekberg M, Brauner A, Wheelock ÅM, Bjermer L, Sköld CM, Lindén A.

Clin Sci (Lond). 2018 May 20;132(9):959-983. doi: 10.1042/CS20180057. Print 2018 May 23.

9.

Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis.

Kärkkäinen M, Nurmi H, Kettunen HP, Selander T, Purokivi M, Kaarteenaho R.

BMC Pulm Med. 2018 May 11;18(1):69. doi: 10.1186/s12890-018-0642-4.

10.

Analysis of the Histologic Features Associated With Interobserver Variation in Idiopathic Pulmonary Fibrosis.

Mäkelä K, Hodgson U, Piilonen A, Kelloniemi K, Bloigu R, Sutinen E, Salmenkivi K, Rönty M, Lappi-Blanco E, Myllärniemi M, Kaarteenaho R.

Am J Surg Pathol. 2018 May;42(5):672-678. doi: 10.1097/PAS.0000000000001031.

PMID:
29438171
11.

NHLRC2 variants identified in patients with fibrosis, neurodegeneration, and cerebral angiomatosis (FINCA): characterisation of a novel cerebropulmonary disease.

Uusimaa J, Kaarteenaho R, Paakkola T, Tuominen H, Karjalainen MK, Nadaf J, Varilo T, Uusi-Mäkelä M, Suo-Palosaari M, Pietilä I, Hiltunen AE, Ruddock L, Alanen H, Biterova E, Miinalainen I, Salminen A, Soininen R, Manninen A, Sormunen R, Kaakinen M, Vuolteenaho R, Herva R, Vieira P, Dunder T, Kokkonen H, Moilanen JS, Rantala H, Nogee LM, Majewski J, Rämet M, Hallman M, Hinttala R.

Acta Neuropathol. 2018 May;135(5):727-742. doi: 10.1007/s00401-018-1817-z. Epub 2018 Feb 8.

PMID:
29423877
12.

Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease.

Nurmi HM, Kettunen HP, Suoranta SK, Purokivi MK, Kärkkäinen MS, Selander TA, Kaarteenaho RL.

Respir Med. 2018 Jan;134:24-30. doi: 10.1016/j.rmed.2017.11.013. Epub 2017 Nov 24.

PMID:
29413504
13.

Interleukin-26 Production in Human Primary Bronchial Epithelial Cells in Response to Viral Stimulation: Modulation by Th17 cytokines.

Che KF, Kaarteenaho R, Lappi-Blanco E, Levänen B, Sun J, Wheelock Å, Palmberg L, Sköld CM, Lindén A.

Mol Med. 2017 Oct;23:247-257. doi: 10.2119/molmed.2016.00064. Epub 2017 Aug 29.

14.

Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis.

Kärkkäinen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R.

Respir Res. 2017 Aug 22;18(1):160. doi: 10.1186/s12931-017-0642-6.

15.

Histological features of malignancy correlate with growth patterns and patient outcome in lung adenocarcinoma.

Mäkinen JM, Laitakari K, Johnson S, Mäkitaro R, Bloigu R, Pääkkö P, Lappi-Blanco E, Kaarteenaho R.

Histopathology. 2017 Sep;71(3):425-436. doi: 10.1111/his.13236. Epub 2017 Jun 16.

PMID:
28401582
16.

Are physicians in primary health care able to recognize pulmonary fibrosis?

Purokivi M, Hodgson U, Myllärniemi M, Salomaa ER, Kaarteenaho R.

Eur Clin Respir J. 2017 Feb 20;4(1):1290339. doi: 10.1080/20018525.2017.1290339. eCollection 2017.

17.

Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Nurmi HM, Purokivi MK, Kärkkäinen MS, Kettunen HP, Selander TA, Kaarteenaho RL.

BMC Pulm Med. 2017 Jan 13;17(1):16. doi: 10.1186/s12890-016-0358-2.

18.

Gender differences in the T-cell profiles of the airways in COPD patients associated with clinical phenotypes.

Forsslund H, Yang M, Mikko M, Karimi R, Nyrén S, Engvall B, Grunewald J, Merikallio H, Kaarteenaho R, Wahlström J, Wheelock ÅM, Sköld CM.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 20;12:35-48. doi: 10.2147/COPD.S113625. eCollection 2017.

19.

Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.

Sköld CM, Bendstrup E, Myllärniemi M, Gudmundsson G, Sjåheim T, Hilberg O, Altraja A, Kaarteenaho R, Ferrara G.

J Intern Med. 2017 Feb;281(2):149-166. doi: 10.1111/joim.12571. Epub 2016 Nov 13. Review.

20.

Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma.

Lappi-Blanco E, Mäkinen JM, Lehtonen S, Karvonen H, Sormunen R, Laitakari K, Johnson S, Mäkitaro R, Bloigu R, Kaarteenaho R.

Tumour Biol. 2016 Oct;37(10):13811-13820. Epub 2016 Aug 1.

PMID:
27481516
21.

Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes.

Nurmi HM, Purokivi MK, Kärkkäinen MS, Kettunen HP, Selander TA, Kaarteenaho RL.

BMC Pulm Med. 2016 Jul 27;16(1):107. doi: 10.1186/s12890-016-0269-2.

22.

Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD.

Balgoma D, Yang M, Sjödin M, Snowden S, Karimi R, Levänen B, Merikallio H, Kaarteenaho R, Palmberg L, Larsson K, Erle DJ, Dahlén SE, Dahlén B, Sköld CM, Wheelock ÅM, Wheelock CE.

Eur Respir J. 2016 Jun;47(6):1645-56. doi: 10.1183/13993003.01080-2015. Epub 2016 Mar 10.

23.

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.

Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S, Zagai U, Sköld MC, Kaarteenaho R.

Respir Res. 2016 Feb 4;17:14. doi: 10.1186/s12931-016-0328-5.

24.

Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine.

Myllärniemi M, Kaarteenaho R.

Eur Clin Respir J. 2015 Feb 10;2. doi: 10.3402/ecrj.v2.26385. eCollection 2015. Review.

25.

Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma.

Mäkinen JM, Laitakari K, Johnson S, Mäkitaro R, Bloigu R, Lappi-Blanco E, Kaarteenaho R.

Lung Cancer. 2015 Dec;90(3):568-74. doi: 10.1016/j.lungcan.2015.10.014. Epub 2015 Oct 17.

PMID:
26506915
26.

Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis.

Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R, Mäkitaro R, Purokivi M, Lappi-Blanco E, Saarelainen S, Kankaanranta H, Mursu A, Kanervisto M, Salomaa ER, Myllärniemi M.

BMC Pulm Med. 2015 Aug 19;15:92. doi: 10.1186/s12890-015-0074-3.

27.

Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis.

Kaarteenaho R, Lappi-Blanco E.

Fibrogenesis Tissue Repair. 2015 Mar 2;8:3. doi: 10.1186/s13069-015-0020-2. eCollection 2015.

28.

Slug is associated with poor survival in squamous cell carcinoma of the lung.

Merikallio H, T TT, Pääkkö P, Mäkitaro R, Kaarteenaho R, Lehtonen S, Salo S, Salo T, Harju T, Soini Y.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5846-54. eCollection 2014.

29.

[Diffuse alveolar damage DAD and organizing pneumonia OP].

Lappi-Blanco E, Jartti A, Kahlos K, Kaarteenaho R.

Duodecim. 2014;130(9):876-81. Review. Finnish.

PMID:
24881139
30.

[Treatment of bronchiectasias].

Purokivi M, Koskela H, Kaarteenaho R.

Duodecim. 2014;130(8):769-77. Review. Finnish.

PMID:
24822326
31.

Stromal cells can be cultured and characterized from diagnostic bronchoalveolar fluid samples obtained from patients with various types of interstitial lung diseases.

Lehtonen ST, Karvonen HM, Harju T, Sormunen R, Lappi-Blanco E, Hilli M, Risteli J, Merikallio H, Kaarteenaho R.

APMIS. 2014 Apr;122(4):301-16. doi: 10.1111/apm.12146.

PMID:
24738160
32.

Lung cancer-associated myofibroblasts reveal distinctive ultrastructure and function.

Karvonen HM, Lehtonen ST, Sormunen RT, Lappi-Blanco E, Sköld CM, Kaarteenaho RL.

J Thorac Oncol. 2014 May;9(5):664-74. doi: 10.1097/JTO.0000000000000149.

33.

Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.

Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllärniemi M.

BMC Pulm Med. 2013 Aug 20;13:53. doi: 10.1186/1471-2466-13-53. Review.

34.

Myofibroblast expression in airways and alveoli is affected by smoking and COPD.

Karvonen HM, Lehtonen ST, Harju T, Sormunen RT, Lappi-Blanco E, Mäkinen JM, Laitakari K, Johnson S, Kaarteenaho RL.

Respir Res. 2013 Aug 11;14:84. doi: 10.1186/1465-9921-14-84.

35.

The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis.

Kaarteenaho R.

Respir Res. 2013 Apr 15;14:43. doi: 10.1186/1465-9921-14-43. Review.

36.

Divergence of tight and adherens junction factors in alveolar epithelium in pulmonary fibrosis.

Lappi-Blanco E, Lehtonen ST, Sormunen R, Merikallio HM, Soini Y, Kaarteenaho RL.

Hum Pathol. 2013 May;44(5):895-907. doi: 10.1016/j.humpath.2012.08.016. Epub 2012 Dec 17.

PMID:
23253490
37.

[Diagnostics of lung cancers becoming more precise].

Lappi-Blanco E, Mäkinen JM, Jartti A, Mali P, Kaarteenaho R.

Duodecim. 2012;128(21):2225-35. Review. Finnish.

PMID:
23210285
38.

Myofibroblasts in interstitial lung diseases show diverse electron microscopic and invasive features.

Karvonen HM, Lehtonen ST, Sormunen RT, Harju TH, Lappi-Blanco E, Bloigu RS, Kaarteenaho RL.

Lab Invest. 2012 Sep;92(9):1270-84. doi: 10.1038/labinvest.2012.95. Epub 2012 Jun 18.

39.

[Idiopathic pulmonary fibrosis -- progress in sight].

Kaarteenaho R, Hodgson U, Myllärniemi M.

Duodecim. 2011;127(24):2639-45. Review. Finnish.

PMID:
22320106
40.

Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders.

Kaarteenaho R, Kinnula VL.

Pulm Med. 2011;2011:531302. doi: 10.1155/2011/531302. Epub 2010 Nov 2.

41.

Tenascin-C and alpha-smooth muscle actin positive cells are increased in the large airways in patients with COPD.

Löfdahl M, Kaarteenaho R, Lappi-Blanco E, Tornling G, Sköld MC.

Respir Res. 2011 Apr 15;12:48. doi: 10.1186/1465-9921-12-48.

42.

[Diffuse pulmonary infiltrates--challenging diagnosis].

Kaarteenaho R, Jartti A.

Duodecim. 2011;127(2):197-207. Review. Finnish.

PMID:
21442870
43.

Zeb1 and twist are more commonly expressed in metastatic than primary lung tumours and show inverse associations with claudins.

Merikallio H, Kaarteenaho R, Pääkkö P, Lehtonen S, Hirvikoski P, Mäkitaro R, Harju T, Soini Y.

J Clin Pathol. 2011 Feb;64(2):136-40. doi: 10.1136/jcp.2010.086678. Epub 2010 Dec 2.

PMID:
21131312
44.

Variability in the precursor proteins of collagen I and III in different stages of COPD.

Harju T, Kinnula VL, Pääkkö P, Salmenkivi K, Risteli J, Kaarteenaho R.

Respir Res. 2010 Nov 30;11:165. doi: 10.1186/1465-9921-11-165.

45.

Impact of smoking on the expression of claudins in lung carcinoma.

Merikallio H, Kaarteenaho R, Pääkkö P, Lehtonen S, Hirvikoski P, Mäkitaro R, Harju T, Soini Y.

Eur J Cancer. 2011 Mar;47(4):620-30. doi: 10.1016/j.ejca.2010.10.017. Epub 2010 Nov 22.

PMID:
21106366
46.

Epithelial N-cadherin and nuclear β-catenin are up-regulated during early development of human lung.

Kaarteenaho R, Lappi-Blanco E, Lehtonen S.

BMC Dev Biol. 2010 Nov 16;10:113. doi: 10.1186/1471-213X-10-113.

47.

Divergent expression of claudin -1, -3, -4, -5 and -7 in developing human lung.

Kaarteenaho R, Merikallio H, Lehtonen S, Harju T, Soini Y.

Respir Res. 2010 May 17;11:59. doi: 10.1186/1465-9921-11-59.

48.

Variable expression of tenascin-C, osteopontin and fibronectin in inflammatory myofibroblastic tumour of the lung.

Kaarteenaho R, Sormunen R, Pääkkö P.

APMIS. 2010 Feb;118(2):91-100. doi: 10.1111/j.1600-0463.2009.02566.x.

PMID:
20132172
49.

[Lung findings in systemic lupus erythematosus].

Mäenpää J, Karjalainen A, Kaarteenaho R.

Duodecim. 2009;125(19):2099-105. Finnish.

PMID:
19938414

Supplemental Content

Loading ...
Support Center